<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Epidemiology of Hepatic Steatosis at a Tertiary Care Center" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/epidemiology-of-hepatic-steatosis-at-a-tertiary-care-center/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/epidemiology-of-hepatic-steatosis-at-a-tertiary-care-center/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2018-02-28T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Epidemiology of Hepatic Steatosis at a Tertiary Care Center" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T03:59:08+00:00","datePublished":"2018-02-28T17:00:00+00:00","description":"Rationale and Objectives","headline":"Epidemiology of Hepatic Steatosis at a Tertiary Care Center","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/epidemiology-of-hepatic-steatosis-at-a-tertiary-care-center/"},"url":"https://clinicaltree.github.io/posts/epidemiology-of-hepatic-steatosis-at-a-tertiary-care-center/"}</script><title>Epidemiology of Hepatic Steatosis at a Tertiary Care Center | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Epidemiology of Hepatic Steatosis at a Tertiary Care Center</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Epidemiology of Hepatic Steatosis at a Tertiary Care Center</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1519837200" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Feb 28, 2018 </em> </span> <span> Updated <em class="" data-ts="1681099148" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Tyler J. Fraum MD</a> </em>, <em> <a href="">Daniel R. Ludwig MD</a> </em>, <em> <a href="">Scott Kilian BS</a> </em>, <em> <a href="">William A. Curtis MD</a> </em>, <em> <a href="">Thomas K. Pilgram PhD</a> </em>, <em> <a href="">Claude B. Sirlin MD</a> </em>, <em> <a href="">Kathryn J. Fowler MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="3711 words"> <em>20 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Little is known about the frequency and risk factors of hepatic steatosis in the tertiary care setting. Such knowledge is essential to clinicians making decisions about testing for this condition. Thus, our aim was to describe the epidemiology of hepatic steatosis, as captured by magnetic resonance imaging (MRI), at a tertiary care center.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>A near-consecutive cohort of 1006 adult patients underwent standard-of-care liver MRIs. Images were retrospectively processed to derive proton density fat fraction (PDFF) maps. Data from three spatially distinct regions of interest (ROIs) were aggregated to derive overall hepatic PDFF values. Demographic, anthropometric, clinical, and laboratory variables were included in a multivariate analysis to determine predictors of hepatic steatosis grades (based on established PDFF cutoffs). Hepatic steatosis grades derived from single vs aggregated ROIs were compared.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Hepatic steatosis was observed in 25% of patients (19% grade 1; 3% grade 2; 3% grade 3). Controlling for all other variables, the odds of hepatic steatosis increased by 7%–9% ( <em>P</em> &lt; .001) for each whole point increase in body mass index (BMI), whereas elevated serum bilirubin was associated with lower odds of hepatic steatosis ( <em>P</em> = .002). Race, diabetes mellitus, dyslipidemia, and metabolic syndrome were not independently predictive of hepatic steatosis when controlling for other variables (eg, BMI). Employing single ROIs (rather than three aggregated ROIs) resulted in incorrect steatosis grading in up to 8.0% of patients.</p><h2 id="conclusion"><span class="mr-2">Conclusion</span><a href="#conclusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Many adult patients undergoing liver MRI at a tertiary care center have hepatic steatosis, with larger BMIs as the only independent predictor of higher grades. This information can be used by clinicians at such centers to make evidence-based decisions about when to test for hepatic steatosis in their patients.</p><h2 id="introduction"><span class="mr-2">Introduction</span><a href="#introduction" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Hepatic steatosis, the abnormal accumulation of lipids within hepatocytes, is a common condition affecting roughly 20%–30% of the population in Western countries . Etiologies of hepatic steatosis have typically been partitioned into nonalcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease. Importantly, the prevalence of NAFLD, which has been linked to nonalcoholic steatohepatitis and cirrhosis, has risen sharply in recent decades, in tandem with the obesity epidemic . Even in the absence of cirrhosis, hepatic steatosis is a risk factor for the development of hepatocellular carcinoma and is associated with insulin resistance and cardiovascular disease .</p><p>The detection of hepatic steatosis is important in guiding clinical management. The current gold standard for diagnosing and grading hepatic steatosis is nontargeted percutaneous biopsy with direct histologic visualization . Although generally safe, percutaneous liver biopsy is an invasive procedure with non-negligible risks of hospitalization (3%) and death (0.01%), with even higher risks of complications in patients with advanced liver disease . Moreover, fat deposition within the hepatic parenchyma can exhibit significant spatial heterogeneity, potentially resulting in undergrading or overgrading due to sampling error . Consequently, there is a need for safe and accurate methods of globally interrogating hepatic fat levels. With the advent of multiecho chemical shift-encoded sequences, magnetic resonance imaging (MRI) has emerged as a reliable, noninvasive means of liver fat quantification .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-identification"><span class="mr-2">Patient Identification</span><a href="#patient-identification" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p>■ <a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p>■ <a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p>■ <a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li>■ <a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-acquisition"><span class="mr-2">Image Acquisition</span><a href="#image-acquisition" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="region-of-interest-selection"><span class="mr-2">Region of Interest Selection</span><a href="#region-of-interest-selection" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EpidemiologyofHepaticSteatosisataTertiaryCareCenter/0_1s20S1076633217304051.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EpidemiologyofHepaticSteatosisataTertiaryCareCenter/0_1s20S1076633217304051.jpg" alt="Figure 1, Methodology for selecting regions of interest (ROIs) within each subject's liver. Three separate circular (~3 cm diameter) two-dimensional ROIs were selected in the central liver (C), right lobe (R), and left lobe (L), using the anatomic multiecho proton density-weighted gradient-recalled echo images ( a ) as a guide to avoid inclusion of large vessels and bile ducts. These same ROIs were propagated into the proton density fat fraction ( b ) and R2* ( c ) maps in equivalent locations." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="liver-fat-quantification-histologic-grade-estimation-and-heterogeneity-assessment"><span class="mr-2">Liver Fat Quantification, Histologic Grade Estimation, and Heterogeneity Assessment</span><a href="#liver-fat-quantification-histologic-grade-estimation-and-heterogeneity-assessment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="liver-iron-quantification-and-histologic-grade-estimation"><span class="mr-2">Liver Iron Quantification and Histologic Grade Estimation</span><a href="#liver-iron-quantification-and-histologic-grade-estimation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-population"><span class="mr-2">Patient Population</span><a href="#patient-population" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 1</p><p>Patient Characteristics</p><p>Liver Fat and Iron Levels Hepatic steatosis Grade 0 (mean PDFF of &lt;5.5%) 75% ( <em>n</em> = 753) Grade 1 (mean PDFF of 5.5–16.2%) 19% ( <em>n</em> = 192) Grade 2 (mean PDFF of 16.3–21.6%) 3% ( <em>n</em> = 30) Grade 3 (mean PDFF of 21.7% or greater) 3% ( <em>n</em> = 31) Hepatic siderosis None (mean LIC of &lt;2.0 mg/g) 90% ( <em>n</em> = 905) Mild (mean LIC of 2.0–7.9 mg/g) 9% ( <em>n</em> = 91) Moderate (mean LIC of 8.0–15.0 mg/g) 1% ( <em>n</em> = 10) Severe (mean LIC of &gt;15.0 mg/g) 0% ( <em>n</em> = 0)</p><p>Demographic Parameters Age (mean ± SEM, y) 57.1 ± 0.4 ( <em>n</em> = 1006) Gender Male 54% ( <em>n</em> = 543) Female 46% ( <em>n</em> = 463) Race White 81% ( <em>n</em> = 813) Black 16% ( <em>n</em> = 160) Asian 1% ( <em>n</em> = 15) Other 2% ( <em>n</em> = 18)</p><p>Risk Factors (RFs) RF-None subgroup None of risk factors below 23% ( <em>n</em> = 230) Any of risk factors below 77% ( <em>n</em> = 776)</p><p>NAFLD-related RFs BMI (mean ± SEM, kg/m 2 ) 28.7 ± 0.2 ( <em>n</em> = 1006) DM Yes 24% ( <em>n</em> = 238) No 76% ( <em>n</em> = 768) Dyslipidemia Yes 20% ( <em>n</em> = 197) No 80% ( <em>n</em> = 809) Metabolic syndrome Yes 4% ( <em>n</em> = 38) No 96% ( <em>n</em> = 968) RF-NAFLD subgroup Any NAFLD-related RFs 42% ( <em>n</em> = 427) No NAFLD-related RFs 58% ( <em>n</em> = 579)</p><p>CLD-related RFs Alcohol abuse within 12 mo Yes 31% ( <em>n</em> = 310) No 69% ( <em>n</em> = 696) Active HCV infection Yes 19% ( <em>n</em> = 196) No 81% ( <em>n</em> = 810) Active HBV infection Yes 2% ( <em>n</em> = 21) No 98% ( <em>n</em> = 985) RF-CLD subgroup Any CLD-related RFs 46% ( <em>n</em> = 461) No CLD-related RFs 54% ( <em>n</em> = 545)</p><p>Cancer-related RFs Liver metastases Yes 8% ( <em>n</em> = 85) No 92% ( <em>n</em> = 921) Chemotherapy within 6 mo Yes 16% ( <em>n</em> = 162) No 84% ( <em>n</em> = 844) RF-CA subgroup Any cancer-related RFs 21% ( <em>n</em> = 214) No cancer related RFs 79% ( <em>n</em> = 792)</p><p>Laboratory Values ALP Normal 56% ( <em>n</em> = 563) Abnormal 44% ( <em>n</em> = 443) tBILI Normal 52% ( <em>n</em> = 519) Abnormal 48% ( <em>n</em> = 487) AST Normal 50% ( <em>n</em> = 498) Abnormal 50% ( <em>n</em> = 508) ALT Normal 59% ( <em>n</em> = 590) Abnormal 41% ( <em>n</em> = 416) Abnormal laboratories Any 75% ( <em>n</em> = 751) None 25% ( <em>n</em> = 255)</p><p>ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; tBILI, total bilirubin; BMI, body mass index; DM, diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; LIC, liver iron concentration; PDFF, proton density fat fraction; RF-CA subgroup, patients with known cancer; RF-CLD subgroup, patients with risk factors for chronic liver disease; RF-NAFLD subgroup, patients with risk factors for non-alcoholic fatty liver disease; RF-None subgroup, patients without any identifiable risk factors; SEM, standard error of the mean.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 2</p><p>Liver Imaging Indications as Provided by Ordering Physician</p><p>Indication Frequency Hepatic metastatic disease 28% ( <em>n</em> = 281) Viral hepatitis ± cirrhosis 24% ( <em>n</em> = 239) Primary liver malignancy (HCC, ICC, H-ChC, etc.) 12% ( <em>n</em> = 119) Other indication 8% ( <em>n</em> = 82) Indeterminate liver mass 6% ( <em>n</em> = 60) Elevated liver enzymes 5% ( <em>n</em> = 47) PSC and/or IBD 4% ( <em>n</em> = 43) Abdominal pain 3.5% ( <em>n</em> = 36) Alcoholic liver disease, including alcoholic cirrhosis 3.5% ( <em>n</em> = 36) Pancreatitis 3% ( <em>n</em> = 28) NAFLD, NASH ± cirrhosis 2% ( <em>n</em> = 23) Iron deposition (known or suspected) 1% ( <em>n</em> = 12)</p><p>HCC, hepatocellular carcinoma; H-ChC, hepato-cholangiocarcinoma; IBD, inflammatory bowel disease; ICC, intrahepatic cholangiocarcinoma; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PSC, primary sclerosing cholangitis.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="predictors-of-hepatic-steatosis"><span class="mr-2">Predictors of Hepatic Steatosis</span><a href="#predictors-of-hepatic-steatosis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 3</p><p>Results of Analysis of Various Demographic, Clinical, and Laboratory Parameters as Individual Predictors of Hepatic Steatosis Grades</p><p>Hepatic Steatosis Grades_P_ Values for Prediction of Hepatic Steatosis Grades 0</p><p>( <em>n</em> = 753) 1</p><p>( <em>n</em> = 192) 2</p><p>( <em>n</em> = 30) 3</p><p>( <em>n</em> = 31)<strong>Demographic parameters</strong> Age (mean ± SEM, y) 57.1 ± 0.5 57.5 ± 0.9 55.5 ± 2.1 55.8 ± 2.0 .83 Gender, <em>n</em> (%) .12 Male 416 (55.3) 93 (48.4) 20 (66.7) 14 (45.2) Female 337 (44.8) 99 (51.6) 10 (33.3) 17 (54.8) Race, <em>n</em> (%) .97 White 606 (80.5) 156 (81.3) 26 (86.7) 25 (80.7) Black 120 (15.9) 31 (16.2) 4 (13.3) 5 (16.1) Asian 12 (1.6) 2 (1.0) 0 (0.0) 1 (3.2) Other 15 (2.0) 3 (1.5) 0 (0.0) 0 (0.0) Risk factors (RFs) RF-None subgroup, <em>n</em> (%) .02 None of risk factors below 188 (25.0) 36 (18.7) 3 (10.0) 3 (9.7) Any of risk factors below 565 (75.0) 156 (81.3) 27 (90.0) 28 (90.3)<strong>NAFLD-related RFs</strong> BMI (mean ± SEM, kg/m 2 ) 27.8 ± 0.2 31.0 ± 0.5 32.1 ± 1.6 32.5 ± 1.8 &lt;.001 \* (larger BMI ➔ higher grades) DM, <em>n</em> (%) Yes 157 (20.8) 58 (30.2) 13 (43.3) 10 (32.2) .001 \* (DM ➔ higher grades) No 596 (79.2) 134 (69.8) 17 (56.7) 21 (77.8) Dyslipidemia, <em>n</em> (%) Yes 129 (17.1) 45 (23.4) 12 (40.0) 11 (35.5) &lt;.001 \* (dyslipidemia ➔ higher grades) No 624 (82.9) 147 (76.6) 18 (60.0) 20 (64.5) Metabolic syndrome, <em>n</em> (%) Yes 19 (2.5) 9 (4.7) 6 (20.0) 4 (12.9) &lt;.001 \* (metabolic syndrome ➔ higher grades) No 734 (97.5) 183 (95.3) 24 (80.0) 27 (87.1) RF-NAFLD subgroup, <em>n</em> (%) Any NAFLD-related RFs 291 (38.7) 99 (51.6) 19 (63.3) 18 (58.1) &lt;.001 \* (any NAFLD-related RFs ➔ higher grades) No NAFLD-related RFs 462 (61.3) 93 (48.4) 11 (36.7) 13 (41.9)<strong>CLD-related RFs</strong> Alcohol abuse within previous 12 mo, <em>n</em> (%) Yes 221 (29.3) 65 (33.9) 14 (46.7) 10 (32.2) .18 No 532 (70.7) 127 (66.1) 16 (53.3) 21 (77.8) Active HCV infection, <em>n</em> (%) Yes 161 (21.4) 30 (15.6) 1 (3.3) 4 (12.9) .02 No 592 (78.6) 162 (84.4) 29 (96.7) 27 (87.1) Active HBV infection, <em>n</em> (%) Yes 16 (2.1) 4 (2.1) 1 (3.3) 0 (0.0) .68 No 737 (97.9) 188 (97.9) 29 (96.7) 31 (100.0) RF-CLD subgroup, <em>n</em> (%) Any CLD-related RFs 348 (46.2) 86 (44.8) 15 (50.0) 12 (38.7) .81 No CLD-related RFs 405 (53.8) 106 (55.2) 15 (50.0) 19 (61.3)<strong>Cancer-related RFs</strong> Liver metastases, <em>n</em> (%) Yes 60 (8.0) 14 (7.3) 5 (16.7) 6 (19.4) .09 No 693 (92.0) 178 (92.7) 25 (83.3) 25 (80.6) Chemotherapy within previous 6 mo, <em>n</em> (%) Yes 120 (15.9) 33 (17.2) 5 (16.7) 4 (12.9) .93 No 633 (84.1) 159 (82.8) 25 (83.3) 27 (87.1) RF-CA subgroup, <em>n</em> (%) Any cancer-related RFs 156 (20.7) 41 (21.4) 8 (26.7) 9 (29.0) .64 No cancer related RFs 597 (79.3) 151 (78.6) 22 (73.3) 22 (71.0)<strong>Laboratory values</strong> ALP, <em>n</em> (%) Normal 395 (52.5) 125 (65.1) 19 (63.3) 24 (77.4) &lt;.001 \* (elevated ALP ➔ lower grades) Abnormal 358 (47.5) 67 (34.9) 11 (36.7) 7 (22.6) tBILI, <em>n</em> (%) Normal 358 (47.5) 127 (66.2) 15 (50.0) 19 (61.3) &lt;.001 \* (elevated tBILI ➔ lower grades) Abnormal 395 (52.5) 65 (33.8) 15 (50.0) 12 (38.7) AST, <em>n</em> (%) Normal 363 (48.2) 103 (53.7) 16 (53.3) 16 (51.6) .56 Abnormal 390 (51.8) 89 (46.4) 14 (46.7) 15 (48.4) ALT, <em>n</em> (%) Normal 436 (57.9) 121 (63.0) 16 (53.3) 17 (54.8) .53 Abnormal 317 (42.1) 71 (37.0) 14 (46.7) 14 (45.2)</p><p>ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DM, diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; RF-CA subgroup, patients with known cancer; RF-CLD subgroup, patients with risk factors for chronic liver disease; RF-NAFLD subgroup, patients with risk factors for nonalcoholic fatty liver disease; RF-None subgroup, patients without any identifiable risk factors; SEM, standard error of the mean; tBILI, total bilirubin.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 4</p><p>Results of Multinomial Logistic Regression Analysis of Various Demographic, Clinical, and Laboratory Parameters as Predictors of Hepatic Steatosis Grades</p><p>Grade 1 † Grade 2 † Grade 3 † L-R χ 2 <em>P</em> Value for Prediction of HFD Grades OR (95% CI) OR (95% CI) OR (95% CI) Demographic parameters Age (continuous) 1.00 (0.99–1.02) 0.98 (0.96–1.01) 0.99 (0.96–1.02) 1.56 .67 Gender (Ref = Female) Male 0.90 (0.76–1.06) 1.35 (0.89–2.06) 0.86 (0.58–1.28) 4.56 .21 Race (Ref = White) Black 1.06 (0.58–1.93) us us 3.88 .92 Asian 0.88 (0.26–2.94) us us Other 1.09 (0.64–1.85) us us Risk factors (RFs) RF-None subgroup (Ref = None) 3.60 .31 Any of risk factors below 1.10 (0.82–1.48) 1.09 (0.49–2.42) 2.41 (0.80–7.27) NAFLD-related RFs BMI (continuous) 1.08 (1.05–1.11) 1.07 (1.00–1.14) 1.09 (1.03–1.16) 33.38 &lt;.001 \* DM (Ref = No) Yes 1.29 (1.00–1.66) 1.54 (0.90–2.65) 1.22 (0.72–2.06) 5.96 .11 Dyslipidemia (Ref = No) Yes 1.20 (0.93–1.56) 1.48 (0.85–2.58) 1.61 (0.93–2.79) 5.55 .14 Metabolic syndrome (Ref = No) Yes 0.90 (0.56–1.43) 1.82 (0.94–3.53) 1.34 (0.66–2.74) 4.25 .24 RF-NAFLD subgroup (Ref = None) Any NAFLD-related RFs 0.78 (0.57–1.08) 0.79 (0.39–1.62) 0.69 (0.36–1.33) 3.30 .35 CLD-related RFs Alcohol abuse within previous 12 mo (Ref = No) Yes 1.14 (0.93–1.40) 1.43 (0.92–2.22) 1.07 (0.69–1.66) 3.58 .31 Active HCV infection (Ref = No) Yes 0.85 (0.66–1.08) 0.41 (0.15–1.14) 0.84 (0.47–1.50) 6.39 .09 Cancer-related RFs Liver metastases (Ref = No) Yes 0.89 (0.64–1.23) 1.64 (0.94–2.86) 1.62 (0.95–2.76) 6.49 .09 Laboratory values ALP (Ref = Normal) Abnormal 0.87 (0.73–1.04) 0.76 (0.50–1.16) 0.62 (0.40–0.98) 7.29 .06 tBILI (Ref = Normal) Abnormal 0.71 (0.59–0.85) 1.06 (0.70–1.59) 0.89 (0.59–1.34) 5.15 .002 \*</p><p>ALP, alkaline phosphatase; BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; HCV, hepatitis C virus; L-R χ 2 , likelihood ratio chi-squared; OR, odds ratio; Ref, reference category; RF-NAFLD subgroup, patients with risk factors for nonalcoholic fatty liver disease; RF-None subgroup, patients without any identifiable risk factors; tBILI, total bilirubin.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="association-between-hepatic-steatosis-and-hepatic-siderosis"><span class="mr-2">Association Between Hepatic Steatosis and Hepatic Siderosis</span><a href="#association-between-hepatic-steatosis-and-hepatic-siderosis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EpidemiologyofHepaticSteatosisataTertiaryCareCenter/1_1s20S1076633217304051.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EpidemiologyofHepaticSteatosisataTertiaryCareCenter/1_1s20S1076633217304051.jpg" alt="Figure 2, Bar graph ( a ) shows the distribution of hepatic siderosis grades among the various grades of hepatic steatosis, with a significant association ( P &lt; .001) between higher siderosis grades and higher steatosis grades. Linear regression ( b ) demonstrates a very weak ( R 2 = 0.01) but significant ( P &lt; .001) positive correlation between mean proton density fat fraction (PDFF) values (a marker of steatosis) and mean field strength-adjusted R2* values (a marker of siderosis). Note that the 20–25 patients with the highest mean field strength-adjusted R2* values (ie, &gt;200) fell at the low end of the range of mean PDFF values ( bracket ), in part related to the much greater frequency of low PDFF values in our study population." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="spatial-heterogeneity-of-hepatic-steatosis"><span class="mr-2">Spatial Heterogeneity of Hepatic Steatosis</span><a href="#spatial-heterogeneity-of-hepatic-steatosis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EpidemiologyofHepaticSteatosisataTertiaryCareCenter/2_1s20S1076633217304051.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EpidemiologyofHepaticSteatosisataTertiaryCareCenter/2_1s20S1076633217304051.jpg" alt="Figure 3, Biopsy simulation shows changes in hepatic steatosis grade that occur when assessing data from solitary liver regions of interest (ROIs) vs data aggregated from all three ROIs. Colored numbers indicate patients whose hepatic steatosis would have been overgraded ( green ) vs undergraded ( red ) had a solitary ROI (ie, simulated tissue sampling) been used. This analysis provides an estimate of the potential for macroscopic sampling errors when assessing hepatic steatosis via a single-site liver biopsy. Abbreviations: Δ = change. (Color version of figure is available online.)" class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="supplementary-data"><span class="mr-2">Supplementary Data</span><a href="#supplementary-data" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table S1</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Scaglioni F., Ciccia S., Marino M., et. al.: ASH and NASH. Dig Dis 2011; 29: pp. 202-210.</p><li><p>2. Lazo M., Clark J.M.: The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: pp. 339-350.</p><li><p>3. Guzman G., Brunt E.M., Petrovic L.M., et. al.: Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008; 132: pp. 1761-1766.</p><li><p>4. Adams L.A., Waters O.R., Knuiman M.W., et. al.: NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: pp. 861-867.</p><li><p>5. Schindhelm R.K., Diamant M., Heine R.J.: Nonalcoholic fatty liver disease and cardiovascular disease risk. Curr Diab Rep 2007; 7: pp. 181-187.</p><li><p>6. Brunt E.M., Janney C.G., Di Bisceglie A.M., et. al.: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: pp. 2467-2474.</p><li><p>7. Rowe J.W., Wands J.R., Mezey E., et. al.: Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred. Medicine (Baltimore) 1977; 56: pp. 197-211.</p><li><p>8. Bravo A.A., Sheth S.G., Chopra S.: Liver biopsy. N Engl J Med 2001; 344: pp. 495-500.</p><li><p>9. Ratziu V., Charlotte F., Heurtier A., et. al.: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: pp. 1898-1906.</p><li><p>10. Wood J.C., Zhang P., Rienhoff H., et. al.: Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. Magn Reson Imaging 2014; 33: pp. 761-767.</p><li><p>11. Reeder S.B., Sirlin C.B.: Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am 2010; 18: pp. 337-357.</p><li><p>12. Sirlin C.B., Reeder S.B.: Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am 2010; 18: pp. 359-381.</p><li><p>13. Yokoo T., Bydder M., Hamilton G., et. al.: Nonalcoholic fatty liver disease: diagnostic and Fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology 2009; 251: pp. 67-76.</p><li><p>14. Pietrangelo A.: Iron and the liver. Liver Int 2016; pp. 116-123.</p><li><p>15. Bydder M., Yokoo T., Hamilton G., et. al.: Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging 2008; 26: pp. 347-359.</p><li><p>16. Meisamy S., Hines C.D.G., Hamilton G., et. al.: Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011; 258: pp. 767-775.</p><li><p>17. Kang G.H., Cruite I., Shiehmorteza M., et. al.: Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J Magn Reson Imaging 2011; 34: pp. 928-934.</p><li><p>18. Szczepaniak L.S., Nurenberg P., Leonard D., et. al.: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: pp. E462-E468.</p><li><p>19. St Pierre T.G., House M.J., Bangma S.J., et. al.: Stereological analysis of liver biopsy histology sections as a reference standard for validating non-invasive liver fat fraction measurements by MRI. PLoS ONE 2016; 11: e0160789</p><li><p>20. Storey P., Thompson A.A., Carqueville C.L., et. al.: R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging 2007; 25: pp. 540-547.</p><li><p>21. Wood J.C., Enriquez C., Ghugre N., et. al.: MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106: pp. 1460-1465.</p><li><p>22. Gomori J.M., Horev G., Tamary H., et. al.: Hepatic iron overload: quantitative MR imaging. Radiology 1991; 179: pp. 367-369.</p><li><p>23. Alústiza J.M., Artetxe J., Castiella A., et. al.: MR quantification of hepatic iron concentration. Radiology 2004; 230: pp. 479-484.</p><li><p>24. Hochberg Y., Benjamini Y.: More powerful procedures for multiple significance testing. Stat Med 1990; 9: pp. 811-818.</p><li><p>25. Bedogni G., Miglioli L., Masutti F., et. al.: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: pp. 44-52.</p><li><p>26. Browning J.D., Szczepaniak L.S., Dobbins R., et. al.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: pp. 1387-1395.</p><li><p>27. Bambha K., Belt P., Abraham M., et. al.: Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55: pp. 769-780.</p><li><p>28. Fernandez F.G., Ritter J., Goodwin J.W., et. al.: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: pp. 845-853.</p><li><p>29. Chang Y., Ryu S., Zhang Y., et. al.: A cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workers. PLoS ONE 2012; 7: e37241</p><li><p>30. Tian J., Zhong R., Liu C., et. al.: Association between bilirubin and risk of non-alcoholic fatty liver disease based on a prospective cohort study. Sci Rep 2016; 6: pp. 31006.</p><li><p>31. Hinds T.D., Hosick P.A., Hankins M.W., et. al.: Mice with hyperbilirubinemia due to Gilbert’s syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα. Am J Physiol Endocrinol Metab 2017; 312: pp. E244-E252.</p><li><p>32. Hopkins P.N., Wu L.L., Hunt S.C., et. al.: Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996; pp. 250-255.</p><li><p>33. Bonekamp S., Tang A., Mashhood A., et. al.: Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging 2014; 39: pp. 1525-1532.</p><li><p>34. Bashir M.R., Zhong X., Nickel M.D., et. al.: Quantification of hepatic steatosis with a multistep adaptive fitting MRI approach: prospective validation against MR spectroscopy. AJR Am J Roentgenol 2015; 204: pp. 297-306.</p><li><p>35. Mamidipalli A., Hamilton G., Manning P., et. al.: Cross-sectional correlation between hepatic R2* and proton density fat fraction (PDFF) in children with hepatic steatosis. J Magn Reson Imaging 2017;</p><li><p>36. Nomura R., Ishizaki Y., Suzuki K., et. al.: Development of hepatic steatosis after pancreatoduodenectomy. Am J Roentgenol 2007; 189: pp. 1484-1488.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-25/'>Volume 25</a>, <a href='/categories/issue-3/'>Issue 3</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Epidemiology%20of%20Hepatic%20Steatosis%20at%20a%20Tertiary%20Care%20Center%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fepidemiology-of-hepatic-steatosis-at-a-tertiary-care-center%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Epidemiology%20of%20Hepatic%20Steatosis%20at%20a%20Tertiary%20Care%20Center%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fepidemiology-of-hepatic-steatosis-at-a-tertiary-care-center%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fepidemiology-of-hepatic-steatosis-at-a-tertiary-care-center%2F&text=Epidemiology%20of%20Hepatic%20Steatosis%20at%20a%20Tertiary%20Care%20Center%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/breast-imaging-outcomes-following-abnormal-thermography/"><div class="card-body"> <em class="small" data-ts="1519837200" data-df="ll" > Feb 28, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Breast Imaging Outcomes following Abnormal Thermography</h3><div class="text-muted small"><p> Rationale and Objectives The study aimed to determine the outcome of patients presenting for evaluation of abnormal breast thermography. Materials and Methods Following Institutional Review Boar...</p></div></div></a></div><div class="card"> <a href="/posts/breast-mri-as-a-problem-solving-study-in-the-evaluation-of-bi-rads-categories-3-and-4-microcalcifica/"><div class="card-body"> <em class="small" data-ts="1519837200" data-df="ll" > Feb 28, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Breast MRI as a Problem-solving Study in the Evaluation of BI-RADS Categories 3 and 4 Microcalcifications</h3><div class="text-muted small"><p> Rationale and Objectives We aimed to investigate the utility of problem-solving breast magnetic resonance imaging (MRI) for mammographic Breast Imaging Reporting and Data System (BI-RADS) categori...</p></div></div></a></div><div class="card"> <a href="/posts/cardiothoracic-mri-in-the-icu/"><div class="card-body"> <em class="small" data-ts="1519837200" data-df="ll" > Feb 28, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Cardiothoracic MRI in the ICU</h3><div class="text-muted small"><p> Rationale and Objective The objective of this study was to identify the feasibility and pitfalls of cardiothoracic magnetic resonance imaging (MRI) in intensive care unit (ICU) patients. Material...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/do-residency-selection-factors-predict-radiology-resident-performance/" class="btn btn-outline-primary" prompt="Older"><p>Do Residency Selection Factors Predict Radiology Resident Performance?</p></a> <a href="/posts/essentials-of-statistical-methods-for-assessing-reliability-and-agreement-in-quantitative-imaging/" class="btn btn-outline-primary" prompt="Newer"><p>Essentials of Statistical Methods for Assessing Reliability and Agreement in Quantitative Imaging</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
